I recently had a video removed from Youtube… and it wasn’t the first time.
In all my communications, I strive to maintain transparency, honesty, professionalism and balance. When discussing medical topics, particularly those related to cancer, I exercise caution, ensuring the accuracy and appropriateness of my statements and word choices.
The latest video to be removed was posted over three years ago for my podcast ‘The Human Guinea Pig Project’, and focused on a drug called dichloroacetate (DCA). In this video, I conducted an interview with an expert well-versed in the clinical application of this drug with patients.
You wouldn’t expect such a conversation to be inherently controversial due to the fact there have been numerous studies on DCA over the years revealing a myriad of potential benefits, with manageable side effects. Many of these studies conclude that DCA holds real promise as a treatment for cancer in specific contexts, with trials still underway.
The discussed video featured an interview with doctor and scientist Dr. Akbar Khan, focusing on the complementary use of DCA in cancer treatment. Dr. Khan is the founder and Medical Director of Medicor Cancer Centres, a cancer clinic which allows patients to receive optimised care by integrating conventional, naturopathic and off-label therapies.
It is important to note that DCA is safe and easily accessible. It is manufactured in the EU and undergoes rigorous laboratory testing. I am acquainted with many individuals who have opted for this treatment and have encountered minimal and manageable side effects.
The audio version of my interview remains accessible as an episode of my podcast series, ‘The Human Guinea Pig Project’. Additionally, I’ve recently uploaded it to Rumble, a platform where I plan to continue sharing more videos. This will enable the dissemination of crucial information that remains uncensorable. It is a shame because I have had to think long and hard about doing this. I still don’t see any of the information I share as controversial.
More about DCA and why it’s so unique:
Firstly, Dichloroacetate is an off label drug, so it’s relatively cheap, easily available, and big pharmaceutical companies can’t make huge profits off of it. It is a small, cheap molecule that has shown promise in preclinical studies over several years.
DCA has been studied for potential use as a cancer treatment due to its ability to modify the metabolism of cancer cells, specifically by inhibiting pyruvate dehydrogenase kinase (PDK), an enzyme involved in cellular energy production. I wrote more extensively on DCA and it’s mechanism of action in my blog in 2017, available here.
If you are familiar with the Warburg Effect, you will know why this is important. Inhibition of PDK with DCA shifts the metabolism of cancer cells from glycolysis to glucose oxidation. As a result we would hope to see restoration of normal mitochondrial function and suppression of mitochondrial dependent apoptosis.
In the context of brain cancer, according to research, it has been shown that human glioblastoma patients require at least a 6.25 mg/kg oral, twice-a-day dose of DCA (Dichloroacetate) to inhibit PDK (Pyruvate dehydrogenase kinase) and kill cancer cells.
While it is true that Dichloroacetate has yet to be proven to be a safe and effective treatment for cancer in large, definitive clinical trials, some early-phase clinical trials have shown that DCA can have some effect on tumour growth in humans.
Addressing safety Concerns:
Dichloroacetate has been associated with a few side effects, including peripheral neuropathy, however this can be managed by supplementing with thiamine (as the drug can cause deficiency), reducing the dose until symptoms subside, or coming off DCA for a short period before returning to it.
Keep reading with a 7-day free trial
Subscribe to Andrew’s Substack to keep reading this post and get 7 days of free access to the full post archives.